Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Earnings data Q3 2026

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Accuray reports strong Q2 results, eyes China growth amid challenges

Accuray's Q2 performance reflects robust growth, particularly in product sales and operational efficiency, positioning the company for future success.
While facing challenges such as market fluctuations and U.S. recovery expectations, Accuray's strategic strengths lie in its service business growth and market expansion in China.
With raised full-year guidance and opportunities to optimize margins and leverage technology recognition, Accuray remains well-positioned for continued growth and innovation.

Accuray reports solid Q3 growth amidst tariff challenges and opportunities

Accuray's Q3 performance reflects revenue growth, operational improvements, and market adaptability. While facing tariff challenges, the company's strategic measures and diverse revenue streams position it well. Opportunities lie in leveraging strong customer demand, tariff mitigation strategies, and service business expansion. Balancing challenges with opportunities will be key for Accuray's continued growth and profitability.

Accuray reports solid Q4 revenue growth, eyes international expansion

Accuray's Q4 performance showcased resilience amid challenges, with a strong focus on international markets and service revenue growth. The company's proactive financial measures and strategic initiatives position it well for growth and margin expansion in FY '26.

Accuray reports Q1 revenue of $94M, focuses on growth strategy

Accuray's Q1 performance reflects a mix of revenue streams, with a focus on innovation and collaboration to drive future growth and profitability. While facing challenges in gross orders and operating losses, the company's strategic initiatives and strong service business position it for long-term success. Opportunities lie in market expansion, margin improvement, and strategic reassessment, signaling a dynamic path forward for Accuray under new leadership.

Accuray reports Q2 revenue decline, focuses on transformation for growth

Accuray faced revenue decline and margin challenges in Q2 2026, driven by lower product margins in China and geopolitical factors. The company's transformation plan aims to mitigate these challenges through cost reduction and margin enhancement in service offerings. Despite setbacks, Accuray remains focused on long-term growth, with revised fiscal 2026 guidance indicating a path towards financial recovery.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.